Advertisement Aviir to raise $30m for TruRisk - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Aviir to raise $30m for TruRisk

Aviir, a biotechnology company, has entered into an agreement with multiple investors to raise $30m in its last financing round to take up commercialization of TruRisk, a cardiac risk assessment technology and of molecular testing services provided through Aviir Heart Laboratories.

Aviir’s TruRisk technology consists of a blood test that measures the blood levels of 7 proteins associated with the development of unstable plaque.

It then uses a complex algorithm to analyze those results and known risk factors to determine an individual’s probability of experiencing a heart attack within the next five years.

Aviir CEO Douglas Harrington said the company intends to determine and prevent cardiovascular diseases through proprietary blood tests and treatment plan recommendations.

The financing includes an initial investment of $10m and future investments of up to $20m upon achieving certain milestones.

The financing round was led by Merck Global Health Innovation Fund and other investors like Bay City Capital, Aberdare Ventures, New Leaf Venture Partners also participated.